King’s Daughters introduces Aquablation Therapy—a new, minimally invasive, robotic-assisted treatment for patients with an enlarged prostate

King’s Daughters Medical Center in Ashland, Ky., announced today that it is the first in Kentucky to offer Aquablation therapy for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The first procedures were performed Wednesday, June 22, 2022.

BPH, or an enlarged prostate, is a non-cancerous condition where the prostate has grown to be larger than normal. One in two men ages 51 to 60 have BPH, and the incidence increases every decade of life. If left untreated, BPH can cause significant health problems, including irreversible bladder or kidney damage, bladder stones, and incontinence.

Aquablation therapy is a different type of treatment for BPH. It’s an advanced, minimally invasive treatment that uses the power of water delivered with robotic precision to provide best-in-class and long-lasting symptom relief, regardless of prostate size or shape.

King’s Daughters urologists Jeremy Bonzo, M.D.; William Boykin, M.D., Justin Dixon, M.D., and Charles Thorndyke, M.D., are the first surgeons to use Aquablation therapy at King’s Daughters.

“We are proud to be the first medical center in Kentucky to offer a solution for men with BPH that provides relief without compromise,” Dixon said. “Aquablation therapy is the next step to furthering our commitment to men’s health.”

About the procedure

Aquablation therapy is performed by the AquaBeam Robotic System, the first FDA-cleared, surgical robot utilizing automated tissue resection or the treatment of lower urinary tract symptoms due to BPH. It combines real-time, multi-dimensional imaging, robotic-assisted technology, and heat-free waterjet ablation for targeted, controlled, and immediate removal of prostate tissue. Aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy, prostate size, or surgeon experience.